MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 573103 | Name: Alemcinal

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Alemcinal is a Gastrointestinal Agent.

Chemical Structure

Alemcinal
Alemcinal
CAS#150785-53-8

Theoretical Analysis

MedKoo Cat#: 573103

Name: Alemcinal

CAS#: 150785-53-8

Chemical Formula: C38H67NO10

Exact Mass: 697.4765

Molecular Weight: 697.95

Elemental Analysis: C, 65.39; H, 9.68; N, 2.01; O, 22.92

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Alemcinal
IUPAC/Chemical Name
8,9-didehydro-N-demethyl-9-deoxo-4', 6, 12-trideoxy-6,9-epoxy-N-ethylerythromycin
InChi Key
IWTSXJNGTTXMFK-KTQUSEMZSA-N
InChi Code
InChI=1S/C38H67NO10/c1-14-28-23(6)30(40)24(7)32-20(3)17-38(11,49-32)34(48-36-31(41)27(39(12)15-2)16-21(4)45-36)25(8)33(26(9)35(42)46-28)47-29-19-37(10,43-13)18-22(5)44-29/h21-31,33-34,36,40-41H,14-19H2,1-13H3/t21-,22+,23+,24-,25+,26-,27+,28-,29+,30+,31-,33+,34-,36+,37+,38-/m1/s1
SMILES Code
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@](C)(C[C@H](C)O2)OC)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)CC)[C@@]4(C)CC(=C(O4)[C@H](C)[C@@H](O)[C@H]1C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 697.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang J, Nong L, Wei Y, Qin S, Zhou Y, Tang Y. Association of osteopontin polymorphisms with nasopharyngeal carcinoma risk. Hum Immunol. 2014 Jan;75(1):76-80. doi: 10.1016/j.humimm.2013.09.014. Epub 2013 Oct 9. PubMed PMID: 24120738. 2: Stevens JE, Jones KL, Rayner CK, Horowitz M. Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives. Expert Opin Pharmacother. 2013 Jun;14(9):1171-86. doi: 10.1517/14656566.2013.795948. Epub 2013 May 11. Review. PubMed PMID: 23663133. 3: Wang CH, Wang LC, Jiang X, Lan L, Liu L, Sun Y, Wang BX. [Effect of interstitial cells of Cajal on gastrointestinal motility induced by motilin receptor agonist ABT-229]. Zhonghua Er Ke Za Zhi. 2010 Apr;48(4):254-9. Chinese. PubMed PMID: 20654011. 4: Mitselos A, Vanden Berghe P, Peeters TL, Depoortere I. Differences in motilin receptor desensitization after stimulation with motilin or motilides are due to alternative receptor trafficking. Biochem Pharmacol. 2008 Mar 1;75(5):1115-28. Epub 2007 Nov 19. PubMed PMID: 18096134. 5: Takanashi H, Yogo K, Ozaki K, Koga H, Itoh Z, Omura S. In vitro pharmacological characterization of mitemcinal (GM-611), the first acid-resistant non-peptide motilin receptor agonist, in smooth muscle of rabbit small intestine. Pharmacology. 2007;79(3):137-48. Epub 2006 Dec 20. PubMed PMID: 17183187. 6: Thielemans L, Depoortere I, Perret J, Robberecht P, Liu Y, Thijs T, Carreras C, Burgeon E, Peeters TL. Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005 Jun;313(3):1397-405. Epub 2005 Mar 11. PubMed PMID: 15764739. 7: Camilleri M. Motilin agonists and dyspepsia: throwing out the baby with the bath water. Gut. 2002 Oct;51(4):612; author reply 612-3. PubMed PMID: 12235094; PubMed Central PMCID: PMC1773416. 8: Netzer P, Schmitt B, Inauen W. Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002 Aug;16(8):1481-90. PubMed PMID: 12182748. 9: Chen CL, Orr WC, Verlinden MH, Dettmer A, Brinkhoff H, Riff D, Schwartz S, Soloway RD, Krause R, Lanza F, Mack RJ. Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002 Apr;16(4):749-57. PubMed PMID: 11929393. 10: Talley NJ, Verlinden M, Geenen DJ, Hogan RB, Riff D, McCallum RW, Mack RJ. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut. 2001 Sep;49(3):395-401. PubMed PMID: 11511562; PubMed Central PMCID: PMC1728418. 11: Talley NJ, Verlinden M, Snape W, Beker JA, Ducrotte P, Dettmer A, Brinkhoff H, Eaker E, Ohning G, Miner PB, Mathias JR, Fumagalli I, Staessen D, Mack RJ. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2000 Dec;14(12):1653-61. PubMed PMID: 11121915. 12: Cowles VE, Nellans HN, Seifert TR, Besecke LM, Segreti JA, Mohning KM, Faghih R, Verlinden MH, Wegner CD. Effect of novel motilide ABT-229 versus erythromycin and cisapride on gastric emptying in dogs. J Pharmacol Exp Ther. 2000 Jun;293(3):1106-11. PubMed PMID: 10869416. 13: Sarna SK, Gonzalez A, Ryan RP. Enteric locus of action of prokinetics: ABT-229, motilin, and erythromycin. Am J Physiol Gastrointest Liver Physiol. 2000 May;278(5):G744-52. PubMed PMID: 10801267. 14: Van Herwaarden MA, Samsom M, Van Nispen CH, Verlinden M, Smout AJ. The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients. Aliment Pharmacol Ther. 2000 Apr;14(4):453-62. PubMed PMID: 10759625. 15: Nieuwenhuijs VB, van Duijvenbode-Beumer H, Verheem A, Visser MR, Verhoef J, Gooszen HG, Akkermans LM. The effects of ABT-229 and octreotide on interdigestive small bowel motility, bacterial overgrowth and bacterial translocation in rats. Eur J Clin Invest. 1999 Jan;29(1):33-40. PubMed PMID: 10092986. 16: Clark MJ, Wright T, Bertrand PP, Bornstein JC, Jenkinson KM, Verlinden M, Furness JB. Erythromycin derivatives ABT 229 and GM 611 act on motilin receptors in the rabbit duodenum. Clin Exp Pharmacol Physiol. 1999 Mar;26(3):242-5. PubMed PMID: 10081621. 17: Furness JB, Clark MJ, Wright T, Bertrand PP, Bornstein JC, Verlinden M. An action of erythromycin in the intestine that is not mediated via motilin receptors. Clin Exp Pharmacol Physiol. 1999 Feb;26(2):100-4. PubMed PMID: 10065328. 18: Verhagen MA, Samsom M, Maes B, Geypens BJ, Ghoos YF, Smout AJ. Effects of a new motilide, ABT-229, on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Aliment Pharmacol Ther. 1997 Dec;11(6):1077-86. PubMed PMID: 9663833. 19: Lartey PA, Nellans HN, Faghih R, Petersen A, Edwards CM, Freiberg L, Quigley S, Marsh K, Klein LL, Plattner JJ. Synthesis of 4"-deoxy motilides: identification of a potent and orally active prokinetic drug candidate. J Med Chem. 1995 May 12;38(10):1793-8. PubMed PMID: 7752203.